Open access
Oct 2026
Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
The trial met its primary endpoint, as enrichment of transcripts associated with activated dendritic cells and immune recruitment pathways was observed in tumors from patients receiving pepinemab-containing regimens, and immune remodeling was evident by formation of mature lymphoid aggregates resembling tertiary lympho...
A. Ruffin, C. Mallow, B. Olson et al.
· Nature Communications · 0 citations